MannKind Reports Topline Results From INFLO-1, Phase 1b Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Dry Powder Inhalation In Patients With Idiopathic Pulmonary Fibrosis

MannKind Files Prospectus For Resale By Selling Stockholders Of Up to 12,853,470 Shares, Including 2,412,632 Shares Underlying Pre-Funded Warrants

Up to 12,853,470 SharesCommon StockThis prospectus supplement relates to the offer and resale by the selling stockholders (the "selling stockholders") identified in this prospectus supplement of up to an

Wells Fargo Maintains Overweight on MannKind, Lowers Price Target to $13

Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and lowers the price target from $14 to $13.

MannKind Q2 Adj. EPS $(0.01) Misses $(0.00) Estimate, Sales $109.374M Beat $108.915M Estimate

MannKind (NASDAQ:MNKD) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $(0.00) by Infinity percent. This is a 120 percent decrease over earnings of $0.05 per share from the

Wells Fargo Maintains Overweight on MannKind, Raises Price Target to $14